#Germany #Munich #Evogene #Systasy #LMU Hospital

Collaborative Efforts Against Inflammatory Diseases

In a significant development for the medical field, Evogene Ltd. (Nasdaq: EVGN), Systasy Bioscience GmbH, and LMU University Hospital Munich have formed a partnership aimed at advancing treatment options for inflammatory diseases linked to neutrophil activities. This collaboration is critically supported by a pan-European EUREKA grant, facilitating the involvement of notable institutions such as the Weizmann Institute of Science from Israel.

Many people globally suffer from inflammatory and immune-mediated disorders where neutrophils—white blood cells vital in defending against infections—play a central role. Notably, these diseases include inflammatory bowel disease (IBD). Traditional therapies often overlook targeting neutrophils directly, leading to a pressing need for innovative and effective treatment strategies.

The collaboration leverages the expertise of various professionals, particularly the insights of Professor Christoph Klein from LMU, whose research stems from studies of a rare immunodeficiency. Through this initiative, the team aims to transform findings from a naturally occurring immune condition into viable therapeutic pathways. Their focus is on developing treatments that can modulate excessive inflammation driven by neutrophils while minimizing the associated safety risks typically linked to immune suppression.

At the helm of this collaboration, Evogene plans to spearhead the small-molecule drug discovery process utilizing its proprietary ChemPass AI™ technology. This AI-driven platform is designed to facilitate the creation, optimization, and prioritization of novel inhibitors that could potentially lead to groundbreaking therapies. By collaborating closely with the Weizmann Institute, the project ensures that computational designs are tested with high-throughput experimental validation, enhancing the likelihood of success.

Systasy Bioscience will harness its advanced DNA barcoding technology to enhance the PathwayProfiler™ platform. This expansion will allow for intricate profiling of stem cell-derived neutrophils to gather functional data necessary for validating and refining Evogene's inhibitors, thereby expediting the discovery phase.

The validation of lead compounds will take place at LMU’s Dr. von Hauner Children's Hospital, where innovative in vitro neutrophil models will be utilized for rigorous testing. The collaboration also incorporates strategies for biomarker discovery and personalized medicine, which are critical for future clinical applications and interventions.

Evogene's President and CEO, Ofer Haviv, expressed enthusiasm regarding the partnership, emphasizing the unique position of ChemPass AI™ in revolutionizing small molecule discovery. He commented on the collaboration's potential to deliver therapeutic solutions for inflammatory diseases that impact countless patients worldwide.

Similarly, Dr. Sven Wichert, the CEO of Systasy, highlighted the pivotal nature of this collaboration in enhancing the PathwayProfiler platform to engage with neutrophil biology. The anticipation is that their combined efforts will yield significant therapeutic innovations addressing critical unmet medical needs associated with hyper-inflammatory conditions.

Professor Christoph Klein also shared his excitement about advancing clinical and scientific knowledge into therapeutic strategies that could substantially impact public health. The EUREKA grant not only validates their collaborative approach but positions them favorably to make meaningful contributions to the treatment of rare diseases.

In summary, this innovative partnership represents a concerted effort across multiple realms of expertise to address the substantial challenges posed by neutrophil-driven inflammatory diseases. With advanced technology, collaborative research dynamics, and the integration of clinical insights, there is a promising trajectory for developing new therapies that could transform the landscape of treatment for these debilitating conditions.